HERCULES, Calif.–(BUSINESS WIRE)–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life
science research and clinical diagnostic products, today announced the
appointment of Dr. Andrew Last as Executive Vice President and Chief
Operating Officer, effective April 22, 2019. In this role, Dr. Last is
responsible for all operating functions of the company on a global basis.
“We are pleased to have Andrew join Bio-Rad and believe his strong
background in global management and leadership spanning the life
science, diagnostics, and pharmaceutical industries coupled with his
technical expertise will be an invaluable asset to Bio-Rad,” said Norman
Schwartz, Bio-Rad President and CEO.
Dr. Last brings over 30 years of global management experience to
Bio-Rad. Most recently he served as Chief Commercial Officer at Berkeley
Lights, Inc. Prior to that he was Chief Operating Officer at Intrexon
From 2010 to 2016 Dr. Last held senior roles at Affymetrix that included
Executive Vice President and Chief Operating Officer. His other past
leadership roles included senior positions with Becton, Dickinson and
Company; Applied Biosystems; Incyte Genomics; and, Monsanto Company.
Dr. Last has a PhD with Agrochemical Specialization and a Master of
Science in Bio-Aeronautics from Cranfield University, UK. He holds of
Bachelor of Science degree from the University of Leicester, UK.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in
developing, manufacturing, and marketing a broad range of innovative
products for the life science research and clinical diagnostic markets.
With a focus on quality and customer service for over 65 years, our
products advance the discovery process and improve healthcare. Our
customers are university and research institutions, hospitals, public
health and commercial laboratories, biotechnology, pharmaceutical, as
well as applied laboratories that include food safety and environmental
quality. Founded in 1952, Bio-Rad is based in Hercules, California, and
has a global network of operations with more than 8,000 employees
worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more
information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, without
limitation, statements we make regarding the expected contributions and
benefits of the new officer. We have based these statements on the
information now known to us. Such statements involve risks and
uncertainties, which could cause actual results to vary materially from
those expressed in or indicated by the forward-looking statements. For
further information regarding our risks and uncertainties, please refer
to the “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operation” in Bio-Rad’s public
reports filed with the Securities and Exchange Commission, including our
most recent Annual Report on Form 10-K and our Quarterly Reports on Form
10-Q. The Company cautions you not to place undue reliance on
forward-looking statements, which reflect an analysis only and speak
only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any
obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications